About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsPharmaceutical Medicines

Diclofenac Sodium Suppository 50mg Non - Steroidal Pharmaceutical Medicines

Have rich experience for this fireld, Competitive price, Fast delivery and Excellent service.

—— Javed Abdullah

A professional company,have a hard working team,very friendly

—— Puvi Manohar

I'm Online Chat Now

Diclofenac Sodium Suppository 50mg Non - Steroidal Pharmaceutical Medicines

China Diclofenac Sodium Suppository 50mg Non - Steroidal Pharmaceutical Medicines supplier
Diclofenac Sodium Suppository 50mg Non - Steroidal Pharmaceutical Medicines supplier Diclofenac Sodium Suppository 50mg Non - Steroidal Pharmaceutical Medicines supplier Diclofenac Sodium Suppository 50mg Non - Steroidal Pharmaceutical Medicines supplier

Large Image :  Diclofenac Sodium Suppository 50mg Non - Steroidal Pharmaceutical Medicines

Product Details:

Place of Origin: China
Brand Name: HL
Certification: GMP
Model Number: 50mg

Payment & Shipping Terms:

Minimum Order Quantity: 50,000 boxes
Price: Negotiation
Packaging Details: 10 Suppositories / Box * 200Box / Carton
Delivery Time: Negotiation
Payment Terms: Western Union, L/C, D/A, T/T
Supply Ability: 1,000,000 boxes per month
Contact Now
Detailed Product Description
Product Name: Diclofenac Sodium Suppository 50mg Composition: Each Suppository Contains 100 Mg Diclofenac Sodium.
Standard: BP/USP Package: 10 Suppositories / Box * 200Box / Carton
Indications: Rheumatoid Arthritis, Osteo-arthritis And Ankylosing Spondylitis. Treatment Of Post Traumatic Pain And Inflammation. For Use As Initial Therapy For Inflammatory And Degenerative Rheumatic Diseases. Storage Instructions: Protect From Moisture. Store Below 25°C. KEEP OUT OF REACH OF CHILDREN.
Expiration Date: 3 Years
High Light:

pharmaceutical drugs


pharma medicines

Diclofenac Sodium suppository 50mg



Each suppository contains 100 mg Diclofenac Sodium.



Diclofenac sodium is a non-steroidal compound with analgesic, anti-inflammatory, antirheumatic and antipyretic properties.
A single 50 mg dose of enteric coated tablets results in maximum plasma concentrations of about 1500 ng/mL at 1,5 to 2 hours after ingestion.
Diclofenac sodium is eliminated principally by metabolism and subsequent urinary and biliary excretion of glucuronide and sulphate conjugates of the metabolites. The principal metabolite in man is the 4-hydroxy derivative of diclofenac sodium. The amount excreted in urine accounts for 20 - 30% of the dose and that in bile for 10 to 20%. The mean terminal elimination half-life is 1,2 to 1,8 hours.



Patients with porphyria. Children under the age of two years.
Patients with a history of active gastro-intestinal bleeding or peptic ulceration. Severe hepatic or renal impairment. Contra-indicated in aspirin-sensitive patients, patients sensitive to any other non-steroidal anti-inflammatory agent, and in patients sensitive to any of the ingredients in these products.
Safety during pregnancy and lactation has not yet been established.
The use of suppositories is contra-indicated in proctitis.



Rheumatoid arthritis, osteo-arthritis and ankylosing spondylitis. Treatment of post traumatic pain and inflammation. For use as initial therapy for inflammatory and degenerative rheumatic diseases.


Serious interactions have been reported after the use of high dose methotrexate with diclofenac.
Caution is required in patients with a history of hypertension and/or heart failure as fluid retention and oedema have been reported in association with  DICLOFENAC therapy.
Elderly: The elderly have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation (PUBs) which may be fatal. 
The risk of gastrointestinal bleeding or perforation (PUBs) is higher with increasing doses of DICLOFENAC, in patients with a history of ulcers, and the elderly.
When gastrointestinal bleeding or ulceration occurs in patients receiving  DICLOFENAC, treatment with  DICLOFENAC should be stopped.
 DICLOFENAC should be given with caution to patients with a history of gastrointestinal disease (eg. ulcerative colitis, Crohn's disease, hiatus hernia, gastro-oesophegeal reflux disease, angiodysplasia) as the condition may be exacerbated. 
Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported. DICLOFENAC should be discontinued at the very first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.



Suppositories should never be divided for administration as active substance may be distributed unevenly.The average adult dose is 50 mg each evening.



Gastro-intestinal disorders, including epigastric pain, eructation, nausea and vomiting may occur.
Peptic ulceration and gastro-intestinal bleeding have been reported. Other side-effects include vertigo, headache, skin rashes, pruritis, tinnitus, depression, drowsiness, nervousness, insomnia, irritability, agitation, minor hearing disorders, oedema, palpitations, blurred vision and other ocular reactions.
Hypersensitivity reactions may occur and include fever and rashes. Hepatotoxicity and aseptic meningitis which occur less frequently may also be hypersensitivity reactions.
Diclofenac may cause cystitis and haematuria, as well as acute renal failure, interstitial nephritis and nephrotic syndrome.
Other adverse effects include anaemia, thrombocytopenia, neutropenia, eosinophilia, agranulocytosis and abnormalities of liver function tests.
Patients with congestive heart failure, cirrhosis, diuretic-induced volume depletion or renal insufficiency are at greater risk of developing renal dysfunction due to non-steroidal anti-inflammatory medicine-induced inhibition of renal prostaglandin synthesis.
It is advisable to perform blood counts in patients undergoing prolonged treatment.
DICLOFENAC should be given with care to patients with cardiovascular disease, bleeding disorders, in those who are receiving coumarin anti-coagulants, and in patients with impaired hepatic or renal function.
Allergic reactions, which include angio-oedema, bronchospasm, urticaria and anaphylactic reactions, have occurred. Because of the possibility of cross-sensitivity due to structural relationships which exist among non-steroidal anti-inflammatory medicines, acute allergic reactions may be more likely to occur in patients who have exhibited allergic reactions to these compounds.
Plasma concentrations are significantly decreased by the concomitant administration of therapeutic doses of aspirin.
When given together with preparations containing lithium or digoxin, diclofenac sodium may raise their plasma concentrations.
Concomitant administration of glucocorticoids or other non-steroidal anti-inflammatory agents may aggravate gastro-intestinal side-effects.
Concomitant administration with two or more non-steroidal anti-inflammatory agents may promote the occurrence of side-effects.
Should be used with caution in patients with asthma or bronchoconstriction.
Use with care in elderly patients.
Decreased platelet aggregation with increased bleeding time may occur.
May increase the half-life of probenecid.
Use with care with other protein-bound medicines e.g. Tolbutamide, Coumarin and Hydantoin.
In view of the product’s inherent potential to cause fluid retention, heart failure may be precipitated in some compromised patients.



Protect from moisture.
Store below 25°C.

Contact Details

Contact Person: Mr. Zhang

Tel: 86--13738134030

Send your inquiry directly to us (0 / 3000)